Patients with multiple myeloma (MM) could be in an increased risk of a more severe COVID-19 infection and of more severe associated complications. In this COVID-19 perspective, associate professor Annette Juul Vangsted goes through newly made clinical guidelines during the COVID-19 pandemic created by The European Myeloma Network.  Multiple myeloma is an incurable cancer in ...

Eric J. Small, MD and principal investigator of the SPARTAN study explains the background and study design of the SPARTAN study, where the efficiency and safety of apalutamide for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) was ...

The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme ‘Unite and Conquer: Accelerating Progress Together.’ This year’s scientific program featured more than 250 oral presentations and 2,500 poster presentations in 24 disease-based and specialty tracks. In the opening session on ...

Results from a post hoc analysis of the SPARTAN Phase III study of apalutamide showed that regardless of genetic subclass, the treatment significantly improved the metastasis-free survival of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). For more than 50% of patients treated with apalutamide, a ≥ 90% reduction in PSA was observed. The results was ...

Three new therapeutic agents for the treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC), apalutamid, darolutamid and enzalutamid, have recently been FDA approved. Not alone are the therapies new, they also open up to the treatment of a whole new group of patients, for whom there was no treatment possibility earlier. It raises several questions. On ...

Dr. David Fajgenbaum was close to dying of Castleman’s disease, but ended up pursuing a cure for this rare disease. In this ASCO podcast episode, Dr. David Fajgenbaum, American immunologist and author, tells about his involvement in finding a cure for the rare Castleman’s disease. He discusses his methodical experiences and relates them to the ...

Martin Reck, MD and Ph.D at the German Center of Lung Research, presented at this year’s ASCO20 Virtual Scientific program the first results from the CheckMate 9LA trial – a randomized trial investigating the combination of a limited cause of chemotherapy together with nivolumab and ipilimumab as first line treatment for patients with advanced non ...

Radiation therapy is an important part of the treatment of hematological malignancies. However, capacity may be reduced because of lack of staff, and exposure of patients and staff by many visits to the oncology center is undesirable. The International Lymphoma Radiation Oncology Group has therefore published emergency guidelines aimed at the COVID-19 situation. In this ...

#Senaste tidskrift

BestPractice Nordic

Nr. 1 • mars 2020
1. Årgang
  • Hjärt-kärlsjukdom
  • Blodtrycksmätning
  • Inkretinbehandling